Baxter acquires $900m oncology portfolio for spin-out-in-waiting
This article was originally published in Scrip
Baxter has bolstered the oncology offering of its soon to be spun out BioScience unit – Baxalta – through the acquisition of the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria of Italy for $900m.
You may also be interested in...
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.